SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001399529-21-000157
Filing Date
2021-11-09
Accepted
2021-11-09 07:47:57
Documents
15
Period of Report
2021-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K drna-20211109.htm   iXBRL 8-K 35044
2 EX-99.1 drna_20211109xex991.htm EX-99.1 77642
6 dicernareports1q19.jpg GRAPHIC 22788
7 drna-20211109_g1.jpg GRAPHIC 64546
  Complete submission text file 0001399529-21-000157.txt   430294

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT drna-20211109.xsd EX-101.SCH 1924
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT drna-20211109_lab.xml EX-101.LAB 23970
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT drna-20211109_pre.xml EX-101.PRE 12656
8 EXTRACTED XBRL INSTANCE DOCUMENT drna-20211109_htm.xml XML 10959
Mailing Address 75 HAYDEN AVENUE LEXINGTON MA 02421
Business Address 75 HAYDEN AVENUE LEXINGTON MA 02421 617 621 8097
Dicerna Pharmaceuticals Inc (Filer) CIK: 0001399529 (see all company filings)

IRS No.: 205993609 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36281 | Film No.: 211389914
SIC: 2834 Pharmaceutical Preparations